Your session is about to expire
← Back to Search
Imaging Techniques for Liver Cancer
Study Summary
This trial will compare PET/MRI and PET/CT to see which is better at diagnosing and managing hepatocellular carcinoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My liver cancer has worsened after local treatment, or I am starting treatment because it was advanced when found.My bilirubin levels are not higher than 3.0 mg/dL.I need urgent surgery for a ruptured or bleeding liver cancer.I am over 18 and willing to give written consent.My liver cancer diagnosis was confirmed by high-level imaging or biopsy.I have not had any treatment for my liver cancer lesion.I may have surgery, a liver transplant, or other liver treatments.
- Group 1: Diagnostic (gallium Ga 68 gozetotide PET/MRI, PET/CT, biopsy)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any open enrolment spots for this trial at present?
"Affirmative. According to clinicaltrials.gov, this research study is actively recruiting patients; it was initially announced on June 5th 2020 and the details were modified most recently on July 18th 2022. 1 site needs to recruit a total of 60 participants for full participation in the trial."
What is the current quota for participants in this research endeavor?
"Affirmative. Clinicaltrials.gov details that this trial, which was initiated on June 5th 2020, is actively recruiting participants. Approximately 60 individuals will be accepted at one of the study sites."
What potential risks accompany Locoregional therapy for people?
"On our risk-assessment scale, we gave locoregional therapy a score of 2 due to the fact that it has been proven safe in Phase 2 trials but efficacy is yet to be established."
Share this study with friends
Copy Link
Messenger